"Characterization of adverse events, health care resource utilization, and real-world survival outcomes with introduction of ibrutinib for chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) patients in BC"

“通过在不列颠哥伦比亚省的慢性淋巴细胞白血病 (CLL)/小淋巴细胞淋巴瘤 (SLL) 患者中引入依鲁替尼来描述不良事件、医疗保健资源利用和现实世界生存结果”

• 批准号: 428899
• 负责人: Khelifi Rania
• 金额: $ 1.27万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-12-01 至 2020-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=428899&lang=en
• 关键词: Adverse Events; Chronic Lymphocytic Leukemia; Clincal Practice; Health Care Resource Utilization; Ibrutinib; Outcomes Research; Population-Level; Real-World; Retrospective; Toxicity

"Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in western countries. A particular drug that has proven to be very effective in newly diagnosed CLL patients and those who have relapsed is ibrutinib. Ibrutinib, however, causes cer

慢性淋巴细胞白血病（CLL）是西方国家成人中最常见的白血病。有一种特殊的药物已被证明对新诊断的CLL患者和复发的患者非常有效，那就是伊鲁替尼。然而，伊鲁替尼会导致癌症